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HIS SYMPOSIUM PROVIDES AN OVERVIEW of the structure and function of the testis and some
T of the perturbations that may be produced in this organ by various agents or endogenous hormones. A discussion of new and traditional diagnostic criteria of testicular proliferative lesions and drug-induced testicular toxicity, along with some pertinent examples of these phenomena, is also provided.
The testis is a common target organ of toxicity. During safety evaluation studies in the rat, neoplasia is often significantly increased in drug-treated animals when these are compared to concurrent controls. Furthermore, difficulties in the diagnosis of proliferative lesions that characterize testicular hyperplasia or neoplasia are often encountered. It is this investigator's experience many compounds induce testicular neoplasia but show no evidence of genotoxicity when tested within in vitro and in vivo mutagenicity assays. Yet many investigators, even today, do not consider the possibility that testicular neoplasia can reflect physiological disturbances or alterations. Tumors of the testis are all too often considered to be a direct carcinogenic effect of the compounds being tested and therefore their further development is curtailed. The primary purpose of this symposium is to discuss, and illustrate with appropriate examples, that toxic and proliferative testicular changes can be caused by secondary mechanisms of action. The case study by Roberts et al. emphasizes this very point by describing the evidence that supported the conclusion that a nongenotoxic mechanism of action induced the Leydig cell tumors observed during the carcinogenicity testing of a calcium channel blocker.
The symposium also underscores a need to understand better the physiological alterations that can be induced by potential therapeutic agents in rodents during subchronic, chronic, and carcinogenicity testing. The understanding of hormonal interactions involved in the regulation of the testis, as described by Nett, is crucial to the proper evaluation and extrapolation of testicular toxicity. Likewise, an awareness of the advantages and shortcomings of sperm assays, such as the flow cytometry methods described by Selden et al. and the sperm head analyses described by Meistrich, may provide important insight into the risk assessment of new pharmaceutical entities. ' Presented at the 1987 Annual Meeting of the Drug Safety Subsection, Pharmaceutical Manufacturers Association, October, 1987, San Antonio, Texas 
